Document Detail

Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor.
MedLine Citation:
PMID:  23269489     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Stent thrombosis (ST), a postinterventional complication with a mortality rate of 50%, has an incidence that rises precipitously in patients at risk. Chronic renal failure and end-stage renal disease have emerged as particularly strong ST risk factors, yet the mechanism remains elusive. Tissue factor (TF) is a crucial mediator of injury-related thrombosis and has been implicated for ST. We posit that uremia modulates TF in the local vessel wall to induce postinterventional thrombosis in patients with end-stage renal disease.
METHODS AND RESULTS: As a model of the de-endothelialized, postinterventional state, we exposed primary human vascular smooth muscle cells (vSMCs) pretreated with uremic serum (obtained from ESRD patients on hemodialysis) to coronary-like blood flow. vSMC TF expression, activity, stability, and posttranslational modification were examined after vSMCs were treated with uremic serum or solutes. We found significantly greater clot formation after uremic serum exposure, which was substantially reduced with the prior treatment with anti-TF neutralizing antibody. Uremic sera induced 2- to 3-fold higher TF expression and activity in vSMCs independent of diabetes mellitus. Relevant concentrations of isolated uremic solutes such as indole-3-acetic acid (3.5 μg/mL), indoxyl sulfate (25 μg/mL), and uric acid (80 μg/mL) recapitulated these effects in cell culture and the flow loop model. We show further that TF undergoes ubiquitination at baseline and that uremic serum, indole-3-acetic acid, and indoxyl sulfate significantly prolong TF half-life by inhibiting its ubiquitination.
CONCLUSIONS: The uremic milieu is profoundly thrombogenic and upregulates vSMC TF levels by increasing TF stability and decreasing its ubiquitination. Together, these data demonstrate for the first time that the posttranslational regulation of TF in uremia may have a causative role in the increased ST risk observed in uremic patients. These data suggest that interventions that reduce vSMC TF may help to prevent ST and that uremic solutes should be considered as novel risk factors for ST in patients with chronic renal failure.
Vipul C Chitalia; Sowmya Shivanna; Jordi Martorell; Mercedes Balcells; Irene Bosch; Kumaran Kolandaivelu; Elazer R Edelman
Related Documents :
2061809 - Intestinal malrotation: the role of small intestinal dysmotility in the cause of persis...
15335409 - Diagnosis and therapy of irritable bowel syndrome.
3319029 - Small bowel obstruction: computer-assisted prediction of strangulation at presentation.
16829389 - The roles of lactose and clostridium difficile in the pathogenesis of enteral feeding a...
20195989 - Diagnostic value of confocal endomicroscopy in celiac disease.
3105959 - Hypoalbuminemia as an indicator of diarrheal incidence in critically ill patients.
7709949 - The value of the clinical history in the differentiation of syncope due to ventricular ...
21380479 - High mobility group protein b1 (hmgb1) in asthma: comparison of patients with chronic o...
10973599 - Visual feedback has differential effects on reaching movements in parkinson's and alzhe...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-12-25
Journal Detail:
Title:  Circulation     Volume:  127     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-22     Completed Date:  2013-04-09     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  365-76     Citation Subset:  AIM; IM    
Harvard-MIT Division of Science and Technology, Bldg E25-449, Massachusetts Institute of Technology, 77 Mass Ave, Cambridge, MA 02139, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Line
Coronary Vessels / drug effects,  metabolism,  pathology
Endothelium, Vascular / drug effects,  metabolism,  pathology
Indican / pharmacology
Indoleacetic Acids / pharmacology
Kidney Failure, Chronic / blood*,  therapy
Middle Aged
Myocytes, Smooth Muscle / drug effects,  metabolism*,  pathology
Renal Dialysis
Risk Factors
Stents / adverse effects*
Thromboplastin / metabolism*
Thrombosis / epidemiology*
Ubiquitination / drug effects
Uremia / blood*
Grant Support
Reg. No./Substance:
0/Indoleacetic Acids; 487-94-5/Indican; 6U1S09C61L/indoleacetic acid; 9035-58-9/Thromboplastin
Comment In:
Circulation. 2013 Jan 22;127(3):320-1   [PMID:  23269490 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression i...
Next Document:  Uremic Serum and Ubiquitylation of Tissue Factor.